President at Sphere3D Inc. in Toronto, Ontario, Canada
Over the last 20 years working with and advising both startups and mature companies, Peter Tassiopoulos has led numerous M&A transactions and helped raise in excess of $200 million of capital for organizations, including early seed rounds all the way through and to senior lending facilities. He has worked with a significant number of companies in various verticals including technology, IT, mining, and gaming.
Peter Tassiopoulos currently serves as the President of Mississauga, Ontario-based virtualization technology solution provider, Sphere 3D Inc.
Sphere 3D is the developer of the multi-patented Glassware 2.0™ technology, which makes it possible for incompatible devices and applications to run over the cloud, without sacrificing performance or security and independent of operating systems or hardware. The company’s technology allows third parties to deliver fully-featured products to any cloud connected device independent of its operating system or hardware.
Peter has led Sphere 3D since 2013. By the end of that same year, the company was ranked as one of the TSX Ventures top performers. In December 2014, Sphere 3D completed a $70M acquisition of Overland-Tandberg, with Peter staying on as President and Vice Chairman of the company.
Prior to his leadership at Sphere 3D, Peter held leadership capacities at other organizations, developing particular expertise in leading technology and healthcare IT-focused companies.
Peter served as the CEO and one of the original founders of Igeacare Systems Inc., where he was responsible for growing the business from 4 employees to more than 120, with sales growing to $20 million annually under his leadership from 2003 to 2008.
Peter also held leadership roles at Biosign Technologies Inc. later in his career. As COO of Biosign Technologies Inc., he was responsible for setting and managing the overall strategy and direction of the company, with a focus specifically on strategic planning, marketing and sales, operations, and R&D efforts. He guided the FDA approval for Biosign’s core technology, which, after his departure, was acquired by Cloud DX and has won numerous awards as one of the world’s most advanced medical devices.
In addition to his various leadership capacities, Peter has had the opportunity to be a speaker on technology and health-related topics.